Gehring, David Austin; Kehler, James Grant
January 1970
Angiology;Jan1970, Vol. 21 Issue 1, p11
Academic Journal
We have successfully treated 20 patients with atrial fibrillation using antazoline hydrochloride (Arithmin) and have converted them to a normal sinus rhythm. The dosage used has varied from 100 mg three times daily to 200 mg four times daily orally. In no case did we use the injectable form. We have observed minimal side effects, although two patients had a parkinsonian reaction which was completely reversible after the drug was discontinued. The drug also has been effective in atrial flutter, premature ventricular contractions and atrial tachycardia.


Related Articles

  • Identification of Hemodynamic Compromise by Cerebrovascular Reserve and Oxygen Extraction Fraction in Occlusive Vascular Disease. Nemoto, Edwin M.; Yonas, Howard; Kuwabara, Hiroto; Pindzola, Ronda R.; Sashin, Donald; Meltzer, Carolyn C.; Price, Julie C.; Yuefang Chang; Johnson, David W. // Journal of Cerebral Blood Flow & Metabolism;Oct2004, Vol. 24 Issue 10, p1081 

    SummaryCerebrovascular reserve (CVR) and oxygen extraction fraction (OEF) are used to identify hemodynamic compromise in symptomatic patients with carotid occlusive vascular disease, but evidence suggests that they are not equivalent. The authors studied the relationship between CVR and OEF to...

  • From rags to riches: the atrial fibrillation story. Delamothe, Tony // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/9/2012, Vol. 344 Issue 7860, p30 

    The author discusses the availability of treatment options available for atrial fibrillation (AF). He cites the heart rhythm week organized by the ArrythmiaAlliance and the National Institute for Health and Clinical Excellence in which attending physicians recommend rivaroxaban as stroke...

  • DU-176b equivalent to warfarin in non-valvular AF. Key, Nigel // Hem/Onc Today;12/25/2008, Vol. 9 Issue 23, p28 

    The article presents the results of a phase-2 study on the use of a once daily dose of DU-176b, an oral Factor Xa inhibitor, as an alternative treatment with warfarin in patients with atrial fibrillation (AF). According to the study, a once daily dose of DU-176b may be a safe alternative...

  • Apixaban: treatment to prevent stroke.  // Nursing & Residential Care;May2013, Vol. 15 Issue 5, p249 

    No abstract available.

  • What's New In... ATRIAL FIBRILLATION: Is dronedarone more effective than amiodarone? BUSHARDT, REAMER L.; JONES, KELLY W. // JAAPA: Journal of the American Academy of Physician Assistants (;Feb2011, Vol. 24 Issue 2, p56 

    The article presents a comparable analysis between dronedarone and amiodarone as effective treatments of atrial fibrillation (AF). It compares the safety of amiodarone and dronedarone based on the potential for proarrhythmia, mortality rate, and other treatment-related adverse events. It...

  • Drug-induced `Parkinson's' linked to Rxs.  // Drug Topics;8/7/95, Vol. 139 Issue 15, p8 

    Reports on a study which investigated the frequency of drug-induced Parkinson's disease in an elderly population. Older people taking drugs for nervous disorders and dementia twice as likely as nonusers to develop symptoms that mimic Parkinson's disease.

  • Physiologic study of the subthalamic volume. Zincone, A.; Landi, A.; Piolti, R.; Appollonio, I.; Mariani, C. B.; Pezzoli, G.; Gaini, S. M.; Frattola, L. // Neurological Sciences;Feb2001, Vol. 22 Issue 1, p111 

    Deep brain stimulation (DBS) obtains good control of advanced PD symptoms. Chronic stimulation of Stn may alleviate rigidity, dyskinesia and tremor. Anatomical and functional intraoperative mapping are mandatory to obtain careful target localisation. Per-operative macrostimulation was carried...

  • PO-RR-069-S.  // Physical Therapy;May1998, Vol. 78 Issue 5, pS24 

    Presents a summary of an article entitled `The Use of Marching Music to Affect Motor Block Characteristics in Parkinsonian Gait,' by T. Blahut, R. Crossen, S. Park, R. Rashleger and M. Moore.

  • Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Haas, Sylvia; Bode, Christoph; Norrving, Bo; Turpie, Alexander G. G. // Vascular Health & Risk Management;2014, Vol. 10, p101 

    Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics